[1] Yamamoto M, Kensler TW, Motohashi H. The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol Rev2018, 98:1169-1203.
[2] Motohashi H, Yamamoto M: Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004, 10:549-557.
[3] Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, Kensler TW, Biswal S: Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006, 116:984-995.
[4] Kong X, Thimmulappa R, Craciun F, Harvey C, Singh A, Kombairaju P, Reddy SP, Remick D, Biswal S: Enhancing Nrf2 pathway by disruption of Keap1 in myeloid leukocytes protects against sepsis. Am J Respir Crit Care Med 2011, 184:928-938.
[5] Yoh K, Itoh K, Enomoto A, Hirayama A, Yamaguchi N, Kobayashi M, Morito N, Koyama A, Yamamoto M, Takahashi S: Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int 2001, 60:1343-1353.
[6] Noel S, Martina MN, Bandapalle S, Racusen LC, Potteti HR, Hamad AR, Reddy SP, Rabb H: T Lymphocyte-Specific Activation of Nrf2 Protects from AKI. J Am Soc Nephrol 2015, 26:2989-3000.
[7] Suzuki T, Murakami S, Biswal SS, Sakaguchi S, Harigae H, Yamamoto M, Motohashi H: Systemic Activation of NRF2 Alleviates Lethal Autoimmune Inflammation in Scurfy Mice. Mol Cell Biol 2017, 37.
[8] Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, Takahashi S, Imakado S, Kotsuji T, Otsuka F, Roop DR, Harada T, Engel JD, Yamamoto M: Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 2003, 35:238-245.
[9] Rice RH, Durbin-Johnson BP, Ishitsuka Y, Salemi M, Phinney BS, Rocke DM, Roop DR: Proteomic Analysis of Loricrin Knockout Mouse Epidermis. J Proteome Res 2016, 15:2560-2566.
[10] Huebner AJ, Dai D, Morasso M, Schmidt EE, Schafer M, Werner S, Roop DR: Amniotic fluid activates the nrf2/keap1 pathway to repair an epidermal barrier defect in utero. Dev Cell 2012, 23:1238-1246.
[11] Ishitsuka Y, Huebner AJ, Rice RH, Koch PJ, Speransky VV, Steven AC, Roop DR: Lce1 Family Members Are Nrf2-Target Genes that Are Induced to Compensate for the Loss of Loricrin. J Invest Dermatol 2016, 136:1656-1663.
[12] Schafer M, Farwanah H, Willrodt AH, Huebner AJ, Sandhoff K, Roop D, Hohl D, Bloch W, Werner S: Nrf2 links epidermal barrier function with antioxidant defense. EMBO Mol Med 2012, 4:364-379.
[13] Capon F, Burden AD, Trembath RC, Barker JN. Psoriasis and other complex trait dermatoses: from Loci to functional pathways. J Invest Dermatol, 2012, 132:915-922.
[14] Basavaraj KH, Vasu Devaraju P, Rao KS. Studies on serum 8-hydroxy guanosine (8-OHdG) as reliable biomarker for psoriasis. J Eur Acad Dermatol Venereol 2013, 27:655-657.
[15] Mrowietz U, Asadullah K: Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 2005, 11:43-48.
[16] Mrowietz U, Szepietowski JC, Loewe R, van de Kerkhof P, Lamarca R, Ocker WG, Tebbs VM, Pau-Charles I: Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm((R)) - and placebo-controlled trial (BRIDGE). Br J Dermatol 2017, 176:615-623.
[17] Tintore M, Sastre-Garriga J: Multiple sclerosis: Dimethyl fumarate is coming of age. Nat Rev Neurol 2016, 12:436-437.
[18] Pinkus H, Mehregan AH: The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Dermatol 1966, 46:109-116.
[19] Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997, 236:313-322.
[20] Durkin ME, Qian X, Popescu NC, Lowy DR: Isolation of Mouse Embryo Fibroblasts. Bio Protoc 2013, 3.
[21] Mehrel T, Hohl D, Rothnagel JA, Longley MA, Bundman D, Cheng C, Lichti U, Bisher ME, Steven AC, Steinert PM, et al.: Identification of a major keratinocyte cell envelope protein, loricrin. Cell 1990, 61:1103-1112.
[22] Imakado S, Bickenbach JR, Bundman DS, Rothnagel JA, Attar PS, Wang XJ, Walczak VR, Wisniewski S, Pote J, Gordon JS, et al.: Targeting expression of a dominant-negative retinoic acid receptor mutant in the epidermis of transgenic mice results in loss of barrier function. Genes Dev 1995, 9:317-329.
[23] Ishitsuka Y, Kawachi Y, Maruyama H, Taguchi S, Fujisawa Y, Furuta J, Nakamura Y, Ishii Y, Otsuka F: Pituitary tumor transforming gene 1 induces tumor necrosis factor-alpha production from keratinocytes: implication for involvement in the pathophysiology of psoriasis. J Invest Dermatol 2013, 133:2566-2575.
[24] Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, Itami S, Nickoloff BJ, DiGiovanni J: Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005, 11:43-49.
[25] Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M: Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999, 13:76-86.
[26] Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Bruck W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, Gold R: Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
[27] Cai Y, Shen X, Ding C, Qi C, Li K, Li X, Jala VR, Zhang HG, Wang T, Zheng J, Yan J: Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011, 35:596-610.
[28] Haas JD, Ravens S, Duber S, Sandrock I, Oberdorfer L, Kashani E, Chennupati V, Fohse L, Naumann R, Weiss S, Krueger A, Forster R, Prinz I: Development of interleukin-17-producing gammadelta T cells is restricted to a functional embryonic wave. Immunity 2012, 37:48-59.
[29] Hawkes JE, Chan TC, Krueger JG: Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017, 140:645-653.
[30] Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, Fouser LA, Renauld JC, Dumoutier L: IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol 2012, 188:462-469.
[31] Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W: Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
[32] Conrad C, Gilliet M: Psoriasis: from Pathogenesis to Targeted Therapies. Clin Rev Allergy Immunol 2018, 54:102-113.
[33] Yang L, Fan X, Cui T, Dang E, Wang G: Nrf2 Promotes Keratinocyte Proliferation in Psoriasis through Up-Regulation of Keratin 6, Keratin 16, and Keratin 17. J Invest Dermatol 2017, 137:2168-2176.
[34] Kerns ML, Guss L, Fahey J, Cohen B, Hakim JM, Sung S, Lu RG, Coulombe PA: Randomized, split-body, single-blinded clinical trial of topical broccoli sprout extract: Assessing the feasibility of its use in keratin-based disorders. J Am Acad Dermatol 2017, 76:449-453 e441.
[35] Kim HJ, Barajas B, Chan RC, Nel AE: Glutathione depletion inhibits dendritic cell maturation and delayed-type hypersensitivity: implications for systemic disease and immunosenescence. J Allergy Clin Immunol 2007, 119:1225-1233.
[36] Ghoreschi K, Bruck J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I, Valtcheva N, Alexander E, Feil S, Feil R, Schulze-Osthoff K, Rupec RA, Lovett-Racke AE, Dringen R, Racke MK, Rocken M: Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011, 208:2291-2303.
[37] Peng H, Guerau-de-Arellano M, Mehta VB, Yang Y, Huss DJ, Papenfuss TL, Lovett-Racke AE, Racke MK: Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem 2012, 287:28017-28026.
[38] Aw Yeang HX, Hamdam JM, Al-Huseini LM, Sethu S, Djouhri L, Walsh J, Kitteringham N, Park BK, Goldring CE, Sathish JG: Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis, and intracellular signaling in dendritic cells. J Biol Chem 2012, 287:10556-10564.
[39] van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP: PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013, 368:1658-1659.
論文の公開元へ
